Acasti Pharma Inc EV/EBIT
Was ist das EV/EBIT von Acasti Pharma Inc?
EV/EBIT von Acasti Pharma Inc ist N/A
Was ist die Definition von EV/EBIT?
Enterprise value to earnings before interest and taxes (EV/EBIT) is a financial ratio used to measure if a stock is priced appropriately to similar stocks and the market. It is similar to the P/E ratio.
ttm (trailing twelve months)
The EV/EBIT ratio addresses some of the shortcomings of the P/E ratio. Instead of taking market capitalization, the ratio uses enterprise value, as it takes into account the true value of the company. Enterprise value includes both equity and debt. It is calculated as:
Enterprise value = market cap + total debt – cash and cash equivalents
The EV/EBIT ratio is useful in comparing peers within the wider market. A high EV/EBIT ratio indicates that a company’s stock is overvalued. On the opposite, a low EV/EBIT ratio indicates that a company’s stock is undervalued. The lower the ratio, the more financially stable a company should be. However, investors and analyst should use other ratios and information to get a full picture of a company’s financial state and actual value.
EV/EBIT von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Acasti Pharma Inc
Was macht Acasti Pharma Inc?
acasti pharma, inc., a subsiduary of neptune technologies & bioressources, is a quebec-based biopharmaceutical dedicated in advancing a proprietary portfolio based on marine phospholipids. our products can be used in prescription, medical food and over-the-counter applications, either as a stand-alone, or, as a fixed-dose combination to exisitng productrs, for the prevention and treatment of cardiometabolic disorders.
Unternehmen mit ev/ebit ähnlich Acasti Pharma Inc
- Halo Collective hat EV/EBIT von N/A
- Nkarta hat EV/EBIT von N/A
- Manugraph India hat EV/EBIT von N/A
- Guild Esports Plc hat EV/EBIT von N/A
- Clarity Gold hat EV/EBIT von N/A
- Radha Madhav hat EV/EBIT von N/A
- Acasti Pharma Inc hat EV/EBIT von N/A
- Akers Biosciences Inc hat EV/EBIT von N/A
- Agios Pharmaceuticals Inc hat EV/EBIT von N/A
- Generation Bio Co hat EV/EBIT von N/A
- Purple Biotech hat EV/EBIT von N/A
- Panbela Therapeutics hat EV/EBIT von N/A
- Continental Materials hat EV/EBIT von N/A